Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Single Ascending Subcutaneous Doses of Sevuparin in Healthy Volunteers
NCT03853421Phase 1Completed
- Sponsor
- Modus Therapeutics
- Start
- Feb 2019
- Primary completion
- May 2019
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sevuparin in sickle cell anemia (SCA) and anemia of chronic kidney disease (4 arms), sponsored by Modus Therapeutics. Primary endpoint: Safety and Tolerability of single ascending subcutaneous doses. Started Feb 2019; status: completed.
02
Drugs
sevuparin
03
Conditions
sickle cell anemia (SCA)anemia of chronic kidney disease
Beyond the preview
Go deeper on NCT03853421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03853421.